These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37404815)

  • 41. Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization.
    Xie H; Wen X; Li J; Chen W; Chen M; Zhang L; Lv M; Zhou S; Bai S; Zhao W; Wang J; Wu J
    Int J Infect Dis; 2022 Apr; 117():97-102. PubMed ID: 35123028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
    Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
    J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamics of CD4
    Zhang W; Liu S; Miao L; Fu A; Bao J; Zheng L; Li E; Yu J; Wang Y
    Infect Drug Resist; 2023; 16():2695-2707. PubMed ID: 37168513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
    Zeng G; He F; Zhang X; Li G; Wang X; Gan Y; Zheng C; Tang J; Xu L; Zhao J; Feng S; Yang Z
    J Med Virol; 2023 May; 95(5):e28797. PubMed ID: 37218584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.
    Corma-Gómez A; Fernández-Fuertes M; Viñuela L; Domínguez C; Santos M; Fuentes-López A; Rojas A; Fernández-Pérez N; Martín-Carmona J; Serrano-Conde E; Real LM; Mendoza J; Macías J; Pineda JA; García F
    J Med Virol; 2023 Mar; 95(3):e28602. PubMed ID: 36880164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China.
    Yan LN; Zhao ZX; Wang ZD; Xiao X; Liu PP; Zhang WK; Gu XL; Li B; Yu LP; Yu XJ
    Expert Rev Vaccines; 2022 Oct; 21(10):1465-1473. PubMed ID: 35861138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of SARS-CoV-2 Breakthrough Infection on HIV Reservoirs and T-Cell Immune Recovery in 3-Dose Vaccinated People Living with HIV.
    Qu MM; Song B; Yang BP; Wang Z; Yu M; Zhang Y; Zhang C; Song JW; Fan X; Xu R; Zhang JY; Zhou CB; Du F; Wang FS; Huang HH; Jiao YM
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
    Terada-Hirashima J; Takamatsu Y; Shimizu Y; Uemura Y; Takeuchi JS; Tomita N; Matsuda K; Maeda K; Yamamoto S; Fukunaga A; Ohmagari N; Mikami A; Sonoda K; Ujiie M; Mitsuya H; Sugiura W
    Hum Vaccin Immunother; 2023 Dec; 19(1):2193074. PubMed ID: 37052247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study.
    Feng Y; Zhang Y; He Z; Huang H; Tian X; Wang G; Chen D; Ren Y; Jia L; Wang W; Wu J; Shao L; Zhang W; Tang H; Wan Y
    EClinicalMedicine; 2022 Jan; 43():101226. PubMed ID: 34901799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China.
    Zhang H; Hua Q; Nani Xu N; Zhang X; Chen B; Ma X; Hu J; Chen Z; Yu P; Lei H; Wang S; Ding L; Fu J; Liao Y; Yang J; Jiang J; Lv H
    Elife; 2023 Mar; 12():. PubMed ID: 36928099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China.
    Han X; Yu X; Han Y; Fang Q; Shen C; Liu H; Wang P; Wang Y; Li X
    Infect Drug Resist; 2022; 15():2091-2100. PubMed ID: 35480056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach.
    Montesi G; Augello M; Polvere J; Marchetti G; Medaglini D; Ciabattini A
    J Transl Med; 2024 May; 22(1):432. PubMed ID: 38715088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
    Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
    mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects.
    Ji R; Zhang J; Liang D; Quan H; Wu Y; Peng A; Li W; Lu S; Zhang X; Ke C; Wang D; Xu J
    Viral Immunol; 2023 Nov; 36(9):593-599. PubMed ID: 37782911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralizing antibody responses assessment after vaccination in people living with HIV using a surrogate neutralization assay.
    Batchi-Bouyou AL; Djontu JC; Ingoba LL; Mougany JS; Mouzinga FH; Dollon Mbama Ntabi J; Kouikani FY; Christ Massamba Ndala A; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Immunol; 2024 Jul; 25(1):43. PubMed ID: 38987686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults.
    Wu Y; Huang P; Xu M; Zhao Q; Xu Y; Han S; Li H; Wang Y
    Front Immunol; 2023; 14():1152899. PubMed ID: 37559719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Willingness of people living with HIV to receive a second COVID-19 booster dose: a multicenter cross-sectional study in China.
    Lan X; Su B; Liang S; Yu M; Qiao Y; Wang L; Song M; Wang Y; Xu J
    Front Public Health; 2023; 11():1227277. PubMed ID: 37680268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study.
    Jia M; Wang X; Gong W; Zhong J; Leng Z; Ren L; Feng L; Guo L; Gao L; Liang X; Chen E; Tang W; Huang Q; Zhang Q; Jiang G; Zhao S; Liu Z; Feng Y; Qi L; Ma L; Huang T; Yue Y; Wang J; Jiang B; Xu L; Wang J; Yang W; Wang C
    J Med Virol; 2022 Dec; 94(12):5746-5757. PubMed ID: 35941840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relatively preserved functional immune capacity with standard COVID-19 vaccine regimen in people living with HIV.
    Hung CY; Hsiao SH; Huang CG; Chang CS; Chen GY; Huang YL; Dutta A; Huang CT
    Front Immunol; 2023; 14():1204314. PubMed ID: 37731482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.